Genmab | GEN - Cash And Equivalent


Genmab reported DKK1.5B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 128.55M 28.9M Sep/2026
Almirall EUR 354.57M 16.8M Jun/2026
Amarin USD 156.51M 12.95M Sep/2026
Amgen USD 13.19B 799M Sep/2026
argenx SE USD 2.6B 984M Sep/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Demant DKK 1.5B 166M Jun/2026
Exelixis USD 304.77M 23.33M Sep/2026
Fresenius Medical Care EUR 1.1B 37.86M Sep/2026
Genmab DKK 1.5B 18M Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
GN Store Nord DKK 685M 121M Sep/2026
GRIFOLS EUR 486M 27M Sep/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Insmed USD 396.56M 148.2M Sep/2026
Lakefront Biotherapeutics EUR 94.66M 41.3M Sep/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 1.96B 788M Jun/2026
Novartis USD 8.87B 1.25B Sep/2026
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024